Company Overview of Kalos Therapeutics, Inc.
Kalos Therapeutics, Inc. develops anti-proliferative drugs for the treatment of cancers and related co-morbidities. It offers KT-220, a drug for the treatment of human cancer cells in human pancreatic, breast, and lung cancers; KTV-111, an animal health drug that leverages the diuretic and therapeutic effects of new chemical entities; and KTH-222, a drug that regulates cell growth via inhibition of the mitogen-activated protein kinase pathway. The company was founded in 2005 and is based in San Diego, California.
4370 La Jolla Village Drive
San Diego, CA 92122
Founded in 2005
Key Executives for Kalos Therapeutics, Inc.
Kalos Therapeutics, Inc. Key Developments
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact Kalos Therapeutics, Inc., please visit www.kalostpx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.